Clevidipine (the Medicines Company)

Zhang, H.

Current Opinion in Investigational Drugs 3(10): 1474-1478

2002


ISSN/ISBN: 1472-4472
PMID: 12431021
Document Number: 541152
The Medicines Company (under license from AstraZeneca) is developing clevidipine, a short-acting dihydropyridine calcium antagonist, for the potential treatment of peri-operative hypertension. By 1997, the compound was undergoing phase II clinical evaluation by the original developer, AstraZeneca. By March 2002, The Medicines Company was conducting phase III clinical trials.

Document emailed within 1 workday
Secure & encrypted payments